

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/662,128	09/14/2000	Shuji Miyagawa	197330US0	9580	
22850	7590 02/06/2002				
OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY			EXAMINER ·		
			QIAN, CELINE X		
ARLINGTON	N, VA 22202		ART UNIT	PAPER NUMBER	
			1633	10	
			DATE MAILED: 02/06/2002	2	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No).	Applicant(s)					
. •		09/662,128	_	MIYAGAWA ET AL.					
	Office Action Summary	Examiner		Art Unit					
		Celine Qian		1636					
Period fo	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status									
1)	Responsive to communication(s) filed on	<u>.</u>							
2a) <u></u> ☐	This action is FINAL . 2b)⊠ This	s action is non-	final.						
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims									
4)[4)⊠ Claim(s) <u>1-21</u> is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.									
5)	Claim(s) is/are allowed.								
6)[6) Claim(s) is/are rejected.								
7)	Claim(s) is/are objected to.								
8)🖾	Claim(s) <u>1-21</u> are subject to restriction and/or e	election requirer	ment.						
Application	on Papers								
9) 🔲 🗆	The specification is objected to by the Examiner	·.							
10)[] 7	The drawing(s) filed on is/are: a)☐ accep	ted or b) Object	cted to by the Exan	niner.					
	Applicant may not request that any objection to the	drawing(s) be h	eld in abeyance. Se	e 37 CFR 1.85(a).					
11) 🔲 🗆	The proposed drawing correction filed on	is: a)∏ approv	/ed b)	ved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.									
12) ☐ The oath or declaration is objected to by the Examiner.									
Priority under 35 U.S.C. §§ 119 and 120									
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a)[☐ All b)☐ Some * c)☐ None of:								
	1. Certified copies of the priority documents	s have been rec	ceived.						
	Certified copies of the priority documents	s have been red	eived in Application	on No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.									
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.									
Attachment(s)									
1) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	(PTO-413) Paper No(s) atent Application (PTO-152)							

Application/Control Number: 09/662,128

Art Unit: 1636

DETAILED ACTION

Claims 1-21 are pending in the application.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-11, drawn to a modified Cre recombinase gene, a cell comprising said

 Cre recombinase gene, a tissue, an organ or an animal comprising Cre

 recombinase gene, classified in class 435, subclass 320.1, class 800, subclass 8.
- II. Claims 13 and 14, drawn to a method of knocking-out a gene from a transgenic animal classified in class 800, subclass 21,
- III. Claims 12, 14 and 15, drawn to a method of knocking-in a gene in a location-controlled manner from a cell, and a transgenic knock-in animal, classified in class 800, subclass 21.
- IV. Claims 16-20, drawn to a transgenic animal from which a second desired gene is knocked-out, and an organ, tissue and cell taken out from the animal, classified in class 800, subclass 21.
- .V. Claim 21, drawn to a method for treating a disease, classified in class 800, subclass 3.

The inventions are distinct, each from the other for the following reasons:

Inventions I and II-V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP

Application/Control Number: 09/662,128

Art Unit: 1636

§ 806.05(h)). In the instant case, the product, a polynucleotide comprising a modified Cre recombinase gene, has other uses besides in the methods mentioned in Groups II-V. For example, the polynucleotide can be used to express Cre recombinase in vitro. Therefore, invention of Group I are patentably distinct from the inventions of Groups II-V.

Inventions II-V are patentably distinct, each from the other because they are drawn to methods that require different starting materials and modes of operation. Each method involves different steps than the others. Therefore, the inventions of Groups II-V are patentably distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X Qian whose telephone number is 703-306-0283. The examiner can normally be reached on 9:00-5:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel can be reached on 703-305-1998. The fax phone numbers for the

Application/Control Number: 09/662,128

Art Unit: 1636

Page 4

organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Celine Qian, Ph.D. January 28, 2002

REMY YUCEL, PH.D
PRIMARY EXAMINER